Statut réglementaire: Composé en développement ; restreint par brevet, usage R&D/soumission réglementaire uniquement
IUPAC Name: N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
EC Number: 806-670-8
Molecular Weight: 506.6
Chemical Formula: C₂₇H₃₂F₂N₈
CAS Number: 1231929-97-7
Application: Inhibiteur de CDK4/6 pour le cancer du sein à récepteurs hormonaux positifs
Status: Pipeline
Development phase: Under development
Therapeutic cat.: Oncology
Polymorphic form: Form III
OEB No.: 4
Samples: Q1 2025

Autres informations

Description supplémentaire:

Abemaciclib (CAS 1231929-97-7, polymorphic Form III) is a pipeline oncology API under development by Polpharma, with samples expected in Q1 2025 at containment level OEB 4. It is a kinase inhibitor used, in combination with aromatase inhibitors or fulvestrant, to treat hormone receptor-positive breast cancer, including advanced and early-stage disease. Polpharma notes the product is intended only for regulatory submission or R&D purposes and is not offered in markets where it remains under patent protection; it is otherwise available across North America, Central/South America, Western and Eastern Europe, Australasia, and Asia.